– UK, Watford – Smith+Nephew (LON: SN / NYSE: SNN), the global medical technology company, announced the appointment of David King to its Board as an independent Non-Executive Director with effect from 1 July 2025.
David King will also join the Compliance & Culture and the Remuneration Committees.
About David King
David King is currently CEO, executive director, and chair of Fortis Life Sciences. He also serves, or has recently served, as a Chair or non-executive director on the boards of several US healthcare companies, including ZimVie (2022 – 2025), VaxCare (2021 – 2025), Privia Health, Health Channels, LG, C, and AmSurg Corporation. David served as executive chair and CEO for Laboratory Corporation of America (LabCorp) from 2007 to 2020 and before that was a partner at Hogan & Hartson LLP (now Hogan Lovells).
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100. The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more: https://www.smith-nephew.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.